Pharma & Biotech Global Week in Review 17 June 09 from IP Think Tank
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/
US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog)
US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent Docs)
Lexapro (Escitalopram) – Australia: Full Federal Court confirms enantiomers patentable for 20 year term: H Lundbeck A/S & Anor v Alphapharm Pty Ltd (Mallesons Stephen Jaques)
Levaquin (Levoflaxacin) – US: CAFC: $1,000,000 in translation costs awarded to prevailing party: Ortho-McNeil Pharmaceutical v Mylan (Patently-O) (Patent Docs) (PatLit) (Patent Baristas)
Generic drug delay called ‘systemic’ problem at TRIPS Council (Intellectual Property Watch)
Panel: EU accord threatens India’s status as top supplier of generic medicines; World Customs body scales back IP enforcement (Intellectual Property Watch)
GAVI, Gates deploy industry-favoured incentive for vaccines to poor countries (Intellectual Property Watch)
WIPO takes stock of latest H1N1 developments (WIPO)
How developing nations can cope with swine flu pandemic (Afro-IP)
EU/India: Troubling times for Indian generic companies – seizure of consignment of Amoxicillin on suspicion of infringement of GSK trade mark (Spicy IP)
South Africa: South Africa’s Bayh Dole Regulations (Spicy IP)
US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent Docs)
US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog)
US: Discussion of Nature/Biotechnology’s summary of Ariad v Lilly (Patents4Life)
US: Biotech/pharma lobbying scoreboard – 1st Quarter ’09 (Patent Docs)
US: As patent cliff nears, more lawsuits filed (GenericsWeb)
Combigan (Brimonidine/Timolol) – US: Allergan files patent infringement suit against Hi-Tech Pharmacal following ANDA to manufacture generic Combigan (Patent Docs)
Kankea (Ubiquinol) – US: Kaneka files patent infringement suit against Pacific Rainbow (S&F)
Levaquin (Levoflaxacin) – US: CAFC: $1,000,000 in translation costs awarded to prevailing party: Ortho-McNeil Pharmaceutical v Mylan (Patently-O) (Patent Docs) (PatLit) (Patent Baristas)
Lexapro (Escitalopram) – Australia: Full Federal Court confirms enantiomers patentable for 20 year term: H Lundbeck A/S & Anor v Alphapharm Pty Ltd (Mallesons Stephen Jaques)
Mucinex (Guaifenesin) – US: Reckitt Benckiser files patent infringement suit against Watson Lab’s following ANDA to manufacture generic Mucinex (Patent Docs)
Nuvaring (Etonogestrel, Ethinyloestradiol) – Australia: Patent Office decision – patent term extension available if has pharmaceutical characteristics: (Patent Baristas)
Ortho Tri-Cyclen LO (Norgestimate, Ethinyl estradiol) – Sandoz sues Johnson & Johnson over contraceptive pill patent (GenericsWeb)
OxyContin (Oxycodone) – US: KV Pharmaceutical Co, Purdue Pharma settle OxyContin patent dispute (SmartBrief)
Solodyn (Minocycline) – US: Medicis files patent infringement suit against Ranbaxy in response to generic Solodyn ANDA (Patent Docs) (GenericsWeb)
You must log in to post a comment.